Novo Nordisk lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back sales of its branded treatments.The Danish company’s sales have been hit by alternative compounded versions of its Ozempic and Wegovy drugs,

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which helped make Novo Europe's most valuable listed company worth $615 billion at its peak, is coming to an end.